This page is updated frequently with new Immune Disease-related patent applications.
| Method for generating t-cells compatible for allogenic transplantation|
The present invention pertains to engineered t-cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered t-cells of the invention are characterized in that the expression of beta 2-microglobulin (b2m) and/or class ii major histocompatibility complex transactivator (ciita) is inhibited, e.g., by using rare-cutting endonucleases able to selectively inactivating by dna cleavage the gene encoding b2m and/or ciita, or by using nucleic acid molecules which inhibit the expression of b2m and/or ciita.
| Ddx5 and associated non-coding rnas and modulation of th17 effector function|
Methods for screening to identify agents capable of modulating ddx5 polypeptide activity are encompassed herein as are methods for using such agents to treat subjects afflicted with th17-mediated inflammatory conditions and autoimmune diseases including, without limitation, crohn's disease, ulcerative colitis, multiple sclerosis, rheumatoid arthritis, and psoriasis and methods for using such agents to treat subjects afflicted with cancer.. .
| Antibody polypeptides that antagonize cd40|
Antibody polypeptides that specifically bind a novel epitope of human cd40 are provided. The antibody polypeptides do not exhibit cd40 agonist activity.
| Inhibitors of bruton's tyrosine kinase|
Disclosed herein are amido compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
| Compound having selective ep2 agonist activity|
A compound represented by general formula (i) wherein all symbols are as defined in the specification, a salt or n-oxide of the compound, or a solvate or prodrug of the compound or the salt or n-oxide has a selective ep2 agonist activity and is highly safe, and is therefore useful as a drug, especially as a therapeutic agent for ep2 receptor-related diseases including immune diseases, allergic diseases, neuronal death, dysmenorrhea, premature birth, miscarriage, baldness, ocular diseases, erectile dysfunction, arthritis, lung injury, pulmonary fibrosis, pulmonary emphysema, bronchitis, chronic obstructive pulmonary disease, bone diseases, cartilage injury and others.. .
Ono Pharmaceutical Co., Ltd.
| Screening the identification of agents capable of activating cd4+cd25+ regulatory t-cells through interactions with the hiv-1 gp120 binding site on cd4|
The present invention relates specific activation of a regulatory t cell via a specific cd4 epitope and uses thereof, e.g. For the treatment of an autoimmune disease or an allergy or asthma or graft rejection or tolerance induction..
| Benzazepine dicarboxamide compounds|
Wherein r1 to r4 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are tlr agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases..
|Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases|
Disclosed herein are compounds that inhibit the activity of anti-apoptotic bcl-2 proteins, compositions containing the compounds and methods of treating diseases using the compounds.. .
|Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors|
The present invention provides a heterocyclic compound having a tlr7, tlr9, tlr7/8, tlr7/9 or tlr7/8/9 inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases, inflammatory diseases and the like, in particular, systemic lupus erythematosus, sjogren's syndrome, rheumatoid arthritis, psoriasis, inflammatory bowel disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof..
Takeda Pharmaceutical Company Limited
Several embodiments of the present disclosure relate to glycotargeting therapeutics that are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired.
École Polytechnique Fédérale De Lausanne (epfl)
Methods and compositions used in treating inflammatory and autoimmune diseases
Methods of treating neuroinflammation by administration of a selective protein c activator, such as recombinant human we thrombin and optionally one or more of its cofactors are disclosed. Also disclosed are pharmaceutical compositions for use in the treatment of mammals that exhibit symptoms of neurological inflammation.
The United States Government As Represented By The Department Of Veterans Affairs
Inhibitors of bruton's tyrosine kinase
Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Anti-mcam antibodies and associated methods of use
The invention provides anti-mcam antibodies that inhibit the ability of human mcam to bind a laminin alpha-4 chain. The invention also provides pharmaceutical compositions, methods of generating such antibodies, and their use in the manufacture of medicaments for treatment of neuroinflammatory disease, autoimmune disease, or cancer..
Prothena Biosciences Limited
Combination treatment for multiple sclerosis
The present application provides evidence that a combined blockade against alpha-4 integrin and mcam is more effective than against either molecule alone. In consequence, the invention provides methods of combination treatment in which both an antagonist of alpha-4 integrin and an mcam antagonist are administered to a subject having or at risk of multiple sclerosis or other autoimmune disease..
University Of Munster
Targeting agent antibody conjugates and uses thereof
Methods, compositions and uses are provided for bispecific antibodies comprising one or more unnatural amino acids. The bispecific antibodies may bind to two or more different receptors, co-receptors, antigens, or cell markers on one or more cells.
The Scripps Research Institute
Compositions and methods for modulating an immune response
Described herein are compositions for increasing il-12 production comprising igg or a fragment thereof or a variant thereof and uses of said compositions for treating cancer and infectious diseases. Also described herein are compositions for decreasing il-12 production comprising an agent that inhibits signaling mediated by interaction between fcrn and igg and uses of said compositions for treating autoimmune diseases.
The Brigham And Women's Hospital, Inc.
A pentacyclic triterpenoid compound with modified structure and preparation method and use thereof
The present invention relates to new pentacyclic triterpenes, their preparation method and use. The compounds of the present invention could effectively treat psoriasis and selectively inhibit in vitro differentiation of the th1 and th17 cells, thereby could be used to treat the th1- or th17-mediated autoimmune diseases..
Suzhou Botany Biomedicals Co., Ltd
Diaryl macrocycles as modulators of protein kinases
The present invention relates to certain diaryl macrocyclic compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating cancer, pain, neurological diseases, autoimmune diseases, and inflammation.. .
Tp Therapeutics, Inc.
Fused amino pyridine as hsp90 inhibitors
The present invention relates to hsp90 inhibitors containing fused amino pyridine core that are useful as inhibitors of hsp90 and their use in the treatment of hsp90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.. .
Immune Disease topics:
Type 1 Diabetes
Signs And Symptoms
Follow us on Twitter
This listing is a sample listing of patent applications related to Immune Disease for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immune Disease with additional patents listed. Browse our RSS directory or Search for other possible listings.